Clinical Trial Update: The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing whether mecobalamin prevents capecitabine-induced hand-foot syndrome; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmar-plantar Erythrodysesthesia

Drugs mentioned

• Mecobalamin (mecobalamin)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Hand-foot Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING